C4 Therapeutics, Inc. (CCCC) Misses Q2 EPS by 1c

C4 Therapeutics, Inc. (NASDAQ: CCCC) reported Q2 EPS of ($0.73), $0.01 worse than the analyst estimate of ($0.72). Revenue for the quarter came in at $2.7 million versus the consensus estimate of $5.39 million.

For earnings history and earnings-related data on C4 Therapeutics, Inc. (CCCC) click here.

You May Also Be Interested In

• C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pret
• Transportadora de Gas del Sur SA (ADR) (TGS) PT Raised to $48 at BofA Securities
• Oracle results beat estimates, but shares fall on plans for $40 billion raise